Abstract
Hypertriglyceridemia is common in antiretroviral therapy-treated patients and Omega 3 fatty acids are being used as a intervention in reducing serum triglycerides (TG) in these patients. The objective of this study is to evaluate the effectiveness of the use of Omega 3 in the treatment of hypertriglyceridemia in HIV/AIDS patients on antiretroviral therapy. This study is a systematic review with meta-analysis of randomized clinical trials. Electronic databases - PubMed, Cochrane and Lilacs were researched. Fifty one articles were encountered. Nine were added to the meta-analysis. The reduction of triglycerides level was -77.55 mg (IC of -121.85 to -33.25) in Omega 3 groups. The analysis considering trials with more than 1000 mg of EPA/DHA included seven studies and the heterogeneity dropped to 0%.The reduction of combined averages was -101.56mg (IC of -145.76 to -57.37). The analysis considering trials with patients that had more than 200 mg/dL of initial triglycerides included also seven trials and the heterogeneity dropped to 0%. The reduction of combined averages was -114.15 mg (IC of -162.34 to -65.97). EPA/DHA supplementation reduces serum triglycerides levels in patients with HIV/AIDS-associated hypertriglyceridemia in stable use of antiretroviral therapy.
Highlights
Activity antiretroviral therapy (HAART) is reducing the morbidity and mortality of HIV-infected patients
The aim of this study is to evaluate the effectiveness of the use of omega 3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients on Highly activity antiretroviral therapy (HAART)
This study consists in a systematic review with meta-analysis of randomized clinical trials to assess the use of Omega 3 fatty acids for the treatment of hypertriglyceridemia in HIV/AIDS patients
Summary
Activity antiretroviral therapy (HAART) is reducing the morbidity and mortality of HIV-infected patients. Treatment is associated to adverse reactions and HIV associated lipodystrophy syndrome characterized by dyslipidemia, glycemic alterations and morphologic alterations as lipoatrophy and lipohypertrophy[3]. In case of dyslipidemia, when associated to HIV-infection, it occurs low HDL levels, total cholesterol and LDL increase (TC) and rise of triglycerides, conditions that favor the risk of cardiovascular disease[4,5]. A few observational studies revealed that the incidence of cardiovascular event in HIV-infected patients on ART is higher than in the overall population[6,7]. Hypertriglyceridemia is one of the most frequent metabolic alterations in ART patients[8]. In a transversal study with 788 patients’ cohort, the authors identified the prevalence of 56% of hypertriglyceridemia[9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
